Phase II trial of pyrazoloacridine in patients with cisplatin-refractory germ cell tumors. Academic Article uri icon

Overview

abstract

  • Thirteen patients with cisplatin-refractory germ cell tumors were treated on a Phase II trial with pyrazoloacridine. Pyrazoloacridine was given intravenously at 600 mg/m2 every three weeks. The median nadir leucocyte count was 2.5 cells/mm3, hemoglobin was 10.8 g/dl, and platelet count was 126,000 cells/m3. None of the thirteen evaluable patients achieved a major response. Pyrazoloacridine is not efficacious in the treatment of cisplatin-refractory germ cell tumors.

publication date

  • August 1, 2000

Research

keywords

  • Acridines
  • Antineoplastic Agents
  • Cisplatin
  • Germinoma
  • Pyrazoles

Identity

Scopus Document Identifier

  • 0033894907

Digital Object Identifier (DOI)

  • 10.1023/a:1006434008357

PubMed ID

  • 10958596

Additional Document Info

volume

  • 18

issue

  • 3